Related Experiment Video

Updated: Oct 8, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Hypoglycaemic episodes in children with insulin dependent diabetes mellitus--can the frequency or severity be

M C McGovern1, D Carson

  • 1The Royal Belfast Hospital for Sick Children, Northern Ireland.

Irish Medical Journal
|April 26, 2001
PubMed

Insights

Significant hypoglycaemic episodes in children with insulin-dependent diabetes mellitus (IDDM) are often unexplained and hard to avoid. Improved support and glucagon use can help manage these events, with early episodes indicating higher recurrence risk.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Metabolic Disorders

Background:

  • Insulin-dependent diabetes mellitus (IDDM) management in children requires careful attention to prevent hypoglycaemic episodes.
  • Hypoglycaemia can lead to severe complications such as seizures and coma.

Purpose of the Study:

  • To evaluate the avoidability and management of significant hypoglycaemic episodes in pediatric IDDM patients.
  • To identify risk factors for recurrent hypoglycaemic events.

Main Methods:

  • Retrospective chart audit of children with IDDM admitted for hypoglycaemia between 1990 and 1997.
  • Analysis of presenting symptoms, causes, glucagon use, and readmission rates.

Main Results:

  • Nine out of 21 children experienced seizures or coma due to hypoglycaemia.
  • Hypoglycaemia was unexplained in 9 cases; only 6 parents utilized glucagon.
  • Five children were readmitted for recurrent hypoglycaemia, with early first episodes (within one year of diagnosis) predicting recurrence.

Conclusions:

  • Hypoglycaemic episodes in pediatric IDDM are frequently unexplained and difficult to prevent entirely.
  • Enhanced support during illness and increased home glucagon use may mitigate frequency and severity.
  • Early hypoglycaemia within the first year of diagnosis is a significant risk factor for recurrent episodes.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...